CKD Biomarkers Consortium Overview
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the CKD Biomarkers Consortium (BioCon) to promote the discovery and validation of biomarkers to advance the field of chronic kidney disease (CKD) research. Phase I of BioCon began in 2009 and will continue into 2016. Phase II of BioCon began in July 2015 with a reconstituted set of investigators and scientific activities.
The NIDDK CKD Biomarkers Consortium brings together investigators whose expertise includes clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification. BioCon is a collaborative effort involving numerous investigators from multiple institutions working together to pursue the development and validation of novel biomarkers for CKD by assaying biological specimens and utilizing data from the nation’s largest epidemiological studies of kidney disease.
Collaborations with the CKD Biomarkers Consortium
Investigators interested in collaborating with the CKD Biomarkers Consortium should contact:
Krista Whitehead, MS
Research Project Manager
Perelman School of Medicine
at The University of Pennsylvania